In a tough fundraising space, cell therapy biotechs pursuing autoimmune indications review staffing to ensure the right expertise is in place to tackle the new disease area.
Cell Therapy Biotechs Hunt for Autoimmune Expertise in Pivot From Oncology Read More »
Dramatic growth in an opaque Medicaid funding mechanism is exacerbating concerns about the program’s fiscal integrity — while spurring financial gains for the hospital industry.
MACPAC calls for greater transparency amid steep rise in Medicaid directed payments Read More »
Baxter will share an update on Hurricane Helene’s impact, while Medtronic will likely discuss a new pulsed field ablation device.
Baxter, Medtronic, Insulet to wrap up medtech earnings Read More »
The deal includes more than 70 urgent care and physical therapy clinics, which Novant said would complement its portfolio in South Carolina.
Novant Health closes UCI Medical Affiliates acquisition Read More »
Government officials and security leaders are hoping the nation’s need for cyber resilience will stand on bipartisan cooperation and transcend partisan politics regardless of the election results.
As presidential election looms, disparate approaches to cyber policy come into focus Read More »
Patient and physician education is the next challenge to change the treatment paradigm for drug-resistant hypertension, Citi Research analyst Joanne Wuensch said.
Medtronic, Recor win CMS transitional payment coverage for renal denervation devices Read More »
BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, but a patient death underscores the need for less-toxic preconditioning treatments.
Patient Death Taints Otherwise Positive Data for Beam’s Sickle Cell Gene Therapy Read More »
About a year after cutting staff by 29%, Sana Biotechnology will trim its workforce as it increases investment in its type 1 diabetes program and looks to extend its cash runway.
Sana Biotechnology Will Lay Off Employees as It Shifts Pipeline Read More »
Last week, the 5th Circuit Court of Appeals sided with the federal government’s original interpretation of the No Surprises Act in determining how a key metric in billing disputes is calculated.
Federal government notches rare win in surprise billing lawsuit Read More »
A suit against Novartis and Vitaris by Henrietta Lacks’ estate hinges on questions about the morality and legality of using the line for biopharmaceutical research.
Lacks Family Lawsuits Seek Share of Profits Stemming from HeLa Cells Read More »
